Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy

Completed

• Conditions: Bronchial Asthma

• Registration Number: NCT01711840
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of the investigation is to confirm the safety of patients receiving Symbicort Turbuhaler as maintenance and reliever therapy ( Symbicort SMART) under the post-marketing actual use.

Detailed Description

Symbicort Turbuhaler 30/60 Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms

Study Timeline

• Study First Submitted: 2012-10-19
• Study First Submitted QC: 2012-10-19
• Study First Posted: 2012-10-22
• Study Start: 2012-11
• Primary Completion: 2015-08
• Study Completion: 2015-08
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-15
• Last Update Posted: 2016-07-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2409

Inclusion Criteria

• Patients receiving Symbicort Turbuhaler as maintenance and reliever therapy for the first time due to 'bronchial asthma ',and possibly requiring as-needed inhalations during the observation period

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse event incidence	12 weeks

Trial Locations

Locations (1)

Research Site; 🇯🇵 Yamanashi, D589ll00001, Japan

Research Site

🇯🇵Yamanashi, D589ll00001, Japan